Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination ...

Amgen (AMGN) closed the most recent trading day at $272.11, moving +0.99% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1% for the day. Meanwhile, ...

which Amgen falls in, has lost 3.8%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business ...

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.

CytomX Therapeutics, a Bay Area biotech firm with lucrative and high-profile partnerships in the industry, is laying off 40% ...

Amgen shows strong clinical progress and ... I will explain in detail why I am a "hold" on the stock. AMGN is a biotechnology company specializing in the development and discovery of innovative ...